



Case report

Invasive *Aspergillus flavus* sinusitis in an immunocompetent patient using intranasal cocaine



Lauren Bougioukas^a, Brendan Campbell^b, Kyle Crooker^b, Jason A. Freed^c, Jonathan Wilcock^b, Devika Singh^{a,b}, Andrew J. Hale^{a,b,*}

^a Lerner College of Medicine, University of Vermont, Burlington, VT, United States

^b University of Vermont Medical Center, Burlington, VT, United States

^c Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

ARTICLE INFO

Article history:

Received 27 October 2021

Received in revised form 1 November 2021

Accepted 1 November 2021

Available online xxxx

Keywords:

Invasive fungal sinusitis

Aspergillosis

Intranasal cocaine

Aspergillus flavus

Maxillary tooth extraction

ABSTRACT

Invasive fungal sinusitis is a rare and potentially fatal infection that tends to occur in immunocompromised hosts. Presented is the case of a 33-year-old immunocompetent male with several months of recurrent facial and nasal pain refractory to several antibacterial courses before a diagnosis of invasive *Aspergillus* sinusitis was made. The patient's symptoms and infection were successfully treated with a combination of surgical debridement and voriconazole. The authors review the epidemiology, risk factors, diagnosis, and treatment of invasive fungal sinusitis due to *Aspergillus*.

© 2021 Published by Elsevier Ltd.
CC-BY-NC-ND 4.0

Introduction

Invasive fungal sinusitis is a dangerous form of infection by *Aspergillus*, with mortality rates as high as 80% [1]. Although invasive infection typically occurs in immunocompromised patients [2–6], other risk factors include hot, dry climates [7–10], farming occupations [3,8,11,12], maxillary tooth extraction [2,11–14], and intranasal cocaine use [5,15]. Diagnosis can be challenging as topical nasal cultures are often negative and symptoms often precede significant radiological findings [8,13,16,17]. Invasive fungal sinusitis left untreated can lead to significant neurological symptoms and mortality rates ranging 28–80% [1,5,16]. Surgical debridement of infected tissue and voriconazole treatment significantly improve symptoms and outcomes [18,19]. Herein, we report a case of invasive fungal sinusitis in an immunocompetent gentleman in the setting of intranasal cocaine use and a recent maxillary canine extraction, who was successfully treated with surgical debridement and voriconazole.

Case presentation

A 33-year-old male from New England presented to infectious diseases (ID) clinic with several months of chronic right facial and right nasal cavity pain. His medical history was significant for intranasal drug use (including cocaine, opioids, and crushed acetaminophen), asthma with occasional fluticasone inhaler use, and gastroesophageal reflux disease. He was a current tobacco smoker with an 18-pack year history, occasional marijuana use, and worked at a laundry cleaning service.

Symptoms began after a right maxillary canine extraction seven months prior to presentation. Three months after symptom onset, he had a computed tomography (CT) scan of the sinuses with contrast which demonstrated sinus drainage occlusion in the right maxillary and sphenoid sinuses. He was treated for acute sinusitis with multiple courses of antibacterials including penicillin, clindamycin, and amoxicillin-clavulanate, as well as nasal saline rinses and oxymetazoline spray, without significant improvement.

Two months prior to presentation, he was seen by an otolaryngologist for symptoms of fevers, chills, headache, nasal congestion, ear pain, blurred vision, and photophobia. On physical exam, he was in mild distress, had right-sided facial tenderness, and poor dentition. A nasal endoscopy showed right septal deflection, purulent discharge, and edema, thought to be consistent with right maxillary and ethmoid sinusitis with significant mucosal

* Correspondence to: University of Vermont Medical Center, Infectious Disease Unit, 111 Colchester Avenue, Mailstop 115 SM2, Burlington, VT 05401, United States.
E-mail address: Andrew.Hale@UVMhealth.org (A.J. Hale).




Fig. 1. Hematoxylin and eosin stain (400x) of sinus tissue demonstrating invasive fungal hyphae with acute angle branching and septations, consistent with *Aspergillus* species.

inflammation. Nasal cultures grew *Aspergillus flavus*, which was initially thought to be environmental contamination. Six weeks prior to presentation, he remained without improvement in symptoms despite ongoing amoxicillin-clavulanate therapy. Repeat nasal endoscopy at that time showed a right-sided septal spur, diffuse edema, purulent discharge, crusting, and an inferior synechia on the right. Antibacterial coverage with amoxicillin-clavulanate was extended and surgery was recommended to clean the sinuses as well as to take tissue and cultures to aid in diagnosis. One month prior to presentation, he underwent right maxillary antrostomy without tissue removal, right anterior ethmoidectomy, debridement of the right nasal cavity, and removal of a right-sided septal spur. Diffuse white-gray necrotic tissue was debrided over the anterior portion of the right nasal cavity, including the inferior and middle turbinate, septum, nasal floor, and uncinata. Cultures from this grew *Aspergillus flavus* with colony morphology consistent with cultures from one month prior. Histopathology of the removed tissue showed tissue invasive branching septate fungal hyphae, consistent with invasive aspergillosis, as well as evidence of crushed pill material, which was thought to be due to snorting (Fig. 1).

One month after surgery (two days prior to ID presentation), his pain and swelling had improved. A third nasal endoscopy at that time showed anterior synechiae at the site of spur and debrided crust from the middle meatus with inflammation. His mucosa appeared to be healing well with no further evidence of pus or necrosis. He had not yet received any antifungals.

On presentation to ID clinic, he was asymptomatic without fevers, chills, right-sided facial pain, right eye pain, or visual changes. On examination, his right nares appeared inflamed, no sinus tenderness was appreciated, and his face and eyes were not swollen. No focal neurological deficits were evident. To rule-out possible intracranial invasion, magnetic resonance imaging (MRI) of the brain and orbits with and without contrast was performed and showed no abnormal intracranial finding and normal appearing orbits. Human immunodeficiency virus (HIV) fourth generation assay, hepatitis B and C serologies, and syphilis serologies were all negative. White blood cells (WBC) were 13,090/ μL (4000–10,400/ μL), absolute neutrophils 9380/ μL (2200–8850/ μL), and absolute eosinophils 390/ μL (30–610/ μL). Electrolytes and liver function tests (LFTs) were normal. His vision was found to be normal by ophthalmology evaluation. Given the histologic diagnosis of invasive aspergillosis sinusitis, antifungal therapy was offered to eliminate residual infection. He was started on voriconazole 200 mg by mouth two times a day for 12 weeks and fluticasone was stopped. He was advised to stop using all intranasal recreational drugs.

Two months after starting voriconazole, the patient reported doing well without any side effects such as visual changes or hallucinations. He had taken voriconazole as directed. Voriconazole

level was normal at 1000 $\mu\text{g/mL}$ (1000–5500 $\mu\text{g/mL}$). Electrolytes and LFTs remained within normal limits. Three months after presentation, he completed voriconazole, and remained without symptoms or side effects. On repeat nasal endoscopy, no polyps, secretions, or evidence of necrosis or fungal infection were present. The patient has remained asymptomatic with no evidence of recurrent clinical symptoms for two years since and has remained abstinent from intranasal drug use.

Discussion

Aspergillus is a ubiquitous environmental mold and is the most common fungus to infect the paranasal sinuses [2]. Invasive fungal sinusitis is a rare fungal disease characterized by tissue destruction, necrosis, and angioinvasion. Mortality rates are high, ranging from 28% to 80%, and is particularly high after the onset of neurological symptoms [1,5,10,16,20]. Although *Aspergillus fumigatus* is the most common species to cause invasive aspergillosis (80–90%), *A. flavus* is less common (5–10%) but more destructive due to toxin production [2–4,11].

Invasive fungal sinusitis generally occurs in the setting of neutropenia, immunosuppressive drugs, diabetes, HIV, trauma, or radiation therapy [2–5]. Other associated factors include male gender [3,10,20,21], asthma [11,12], use of inhalational steroids [1,12], marijuana use [12], heavy smoking [3], individuals in the 3rd or 4th decade of life [10,21], alcoholism [13,22], farming occupation [3,8,11,12], trauma or a surgical procedure such as implantation of prosthetic material [16], septal surgery [20], and endemic locations such as the Middle East, Indian sub-continent, and Southern United States [7–9] likely due to hot, dry climates [10].

The diagnosis of invasive fungal sinusitis can be challenging as illustrated in this case. Patients often present with several months of symptoms such as headache, nasal congestion, fever, and maxillary region facial pain, especially in the setting of refractory or recurrent sinusitis [2,5,7,10,12,14,21,23,24]. Neurological symptoms are associated with a greater risk of mortality [10,12,13,20,22]. Although the patient illustrated here was otherwise mostly healthy, he likely acquired the infection through his maxillary tooth extraction, intranasal drug use, or a combination of both. In the literature, we identified five prior case reports of invasive aspergillosis occurring after a maxillary tooth extraction [2,11–14], and two prior reports of *A. flavus* invasive sinusitis in the setting of intranasal cocaine use [5,15]. Cocaine is thought to cause vasoconstriction, mucosal inflammation, and changes to the mucociliary clearance mechanism that can subsequently lead to local ulceration, tissue ischemia, and tissue necrosis enabling *Aspergillus* to thrive in the decomposing organic material, especially in the setting of nasal moisture [5,15,21].

The diagnosis of invasive fungal sinusitis is established with tissue histologic examination and fungal culture via tissue biopsy. It is important to note that surface cultures are often negative, and symptoms may precede radiological findings [8,13,16,17]. In one case series only 10 of 16 (63%) patients with invasive sinusitis from aspergillosis had a positive culture [21]. Another study found that as high as 75% of infected individuals had false negative surface cultures [23]. Further difficulties include poor accessibility to the sinus without procedural intervention [23]. A high index of suspicion for fungal invasive sinusitis must be maintained when a patient with risk-factors has sinusitis refractory to traditional antibacterial therapies. In addition to fungal sinusitis, other causes of antibacterial refractory sinusitis include malignancy and systemic vasculitis [25–27].

As illustrated here, surgery is of paramount importance for both diagnosis and treatment. Non-invasive disease (allergic aspergillosis or aspergilloma) can convert to semi-invasive (locally destructive disease without tissue invasion), or invasive disease without adequate debridement and antifungal treatment [4,9,12,13,28,29]. This

is illustrated in one case report where non-invasive disease converted to invasive disease in an elderly patient [29]. Longer duration of symptoms is associated with progression to intra-cranial disease and possible dural invasion, which carries a high risk of mortality [7–10]. Additionally, *Aspergillus* can occlude the vascular supply and inhibit anti-fungal treatment from reaching infected areas [22]. Lastly, as seen here, symptoms can significantly improve with surgery, prior to starting anti-fungal therapy.

In combination with surgery, a variety of anti-fungal agents have been used to successfully treat invasive sinusitis from aspergillosis. Historically, amphotericin B was used for treatment, though is associated with significant side effects such as renal and hepatic toxicities, anemia, fever, and electrolyte disturbances [2,3,12,21,28]. Itraconazole and echinocandin have also been used [11,12,15]. In 2016, the Infectious Diseases Society of America (IDSA) updated guidelines and recommended voriconazole to be the primary treatment of invasive syndromes of *Aspergillus* [18]. Voriconazole is more effective and poses fewer side effects than amphotericin B [19].

In summary, early diagnosis and treatment of invasive sinusitis from aspergillosis is critical to prevent disease progression. However, diagnosis can be difficult. Although invasive aspergillosis tends to infect immunocompromised patients, it should be included in the differential when patients with a history of recent intranasal drug use or maxillary tooth extraction present with refractory sinusitis.

Funding

None.

Authorship verification

All co-authors have seen and agree with the contents of the manuscript and have contributed significantly to the work.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

CRedit authorship contribution statement

Lauren Bougioukas: conceptualization, writing: original draft; writing: review & editing, **Brendan Campbell:** conceptualization, writing: original draft; writing: review & editing, **Kyle Crooker:** conceptualization, writing: original draft; writing: review & editing, **Jason A. Freed:** conceptualization, writing: original draft; writing: review & editing, **Jonathan Wilcock:** conceptualization, writing: original draft; writing: review & editing, **Devika Singh:** conceptualization, writing: original draft; writing: review & editing, **Andrew J. Hale:** conceptualization, patient care, writing: original draft; writing: review & editing.

Conflict of interests statement

None of the authors report any conflicts of interest.

Acknowledgments

None.

References

- [1] Bratton RL, Brazis PW, Hellinger WC, Wharen Jr. RE, Broderick DF. Aspergillosis related to long-term nasal corticosteroid use. *Mayo Clin Proc* 2002;77(12):1353–7.
- [2] Peral-Cagigal B, Redondo-Gonzalez LM, Verrier-Hernandez A. Invasive maxillary sinus aspergillosis: a case report successfully treated with voriconazole and surgical debridement. *J Clin Exp Dent* 2014;6(4):e448–51.
- [3] Syed A, Panta P, Shahid I, Felix DH. Invasive aspergillosis associated with a foreign body. *Case Rep Pathol* 2015;2015:875168.
- [4] Dhirawani R, Asrani S, Pathak S, Sharma A. Facial translocation approach for management of invasive sinonasal aspergillosis. *J Maxillofac Oral Surg* 2015;14(Suppl 1):482–7.
- [5] Pekala KR, Clavenna MJ, Shockley R, Weiss VL, Turner JH. Chronic invasive fungal sinusitis associated with intranasal drug use. *Laryngoscope* 2015;125(12):2656–9.
- [6] Cha SA, Kim MH, Lim TS, et al. Invasive primary colonic aspergillosis in the immunocompetent host without classical risk factors. *Yonsei Med J* 2015;56(5):1453–6.
- [7] Dhiwakar M, Thakar A, Bahadur S. Invasive sino-orbital aspergillosis: surgical decisions and dilemmas. *J Laryngol Otol* 2003;117(4):280–5.
- [8] de Martin Truzzi C, Furlan Pauna H, Moreira, Hazboun I, et al. Slowly progressive invasive rhino-orbital-cerebral aspergillosis: case report and literature review. *Clin Case Rep* 2017;5(3):218–24.
- [9] Kameswaran M, al-Wadei A, Khurana P, Okafor BC. Rhinocerebral aspergillosis. *J Laryngol Otol* 1992;106(11):981–5.
- [10] Tyagi I, Taneja HC. Rhinocerebral invasive aspergillosis. *Indian J Otolaryngol Head Neck Surg* 1998;50(1):26–32.
- [11] Sethi P, Saluja R, Jindal N, Singh V. Invasive aspergillosis in an immunocompetent host. *J Oral Maxillofac Pathol* 2012;16(2):297–300.
- [12] Singhal SK, Dass A, Singh GB, Punia RP, Nagarkar NM. Destructive aspergillosis. *Indian J Otolaryngol Head Neck Surg* 2005;57(3):244–6.
- [13] Tamgadge AP, Mengi R, Tamgadge S, Bhalerao SS. Chronic invasive aspergillosis of paranasal sinuses: a case report with review of literature. *J Oral Maxillofac Pathol* 2012;16(3):460–4.
- [14] Yan B, Wu X, Zhou D. Invasive intracranial aspergillosis in an immunocompetent patient after dental extraction. *Scand J Infect Dis* 2011;43(2):156–8.
- [15] Azulay-Abulafia L, Sousa MA, Pussanti A, Coimbra DD, Vega H, Bernardes Filho F. Invasive aspergillosis in a user of inhaled cocaine: rhinosinusitis with bone and cartilage destruction. *Rev Soc Bras Med Trop* 2014;47(4):533–6.
- [16] Schwartz S, Thiel E. Clinical presentation of invasive aspergillosis. *Mycoses* 1997;40(Suppl 2):21–4.
- [17] Hartwick RW, Batsakis JG. Sinus aspergillosis and allergic fungal sinusitis. *Ann Otol Rhinol Laryngol* 1991;100(5 Pt 1):427–30.
- [18] Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. *Clin Infect Dis* 2016;63(4):e1–60.
- [19] Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med* 2002;347(6):408–15.
- [20] Smith A, Thimmappa V, Shepherd B, Ray M, Sheyn A, Thompson J. Invasive fungal sinusitis in the pediatric population: systematic review with quantitative synthesis of the literature. *Int J Pediatr Otorhinolaryngol* 2016;90:231–5.
- [21] Rao JJ, Vinaya Kumar EC, Chowdary VS, Kumar N, Reddy KJ. Invasive Sino Nasal Aspergillosis diagnostic criteria. *Indian J Otolaryngol Head Neck Surg* 2001;53(4):295–8.
- [22] Mauriello Jr. JA, Yopez N, Mostafavi R, et al. Invasive rhinosino-orbital aspergillosis with precipitous visual loss. *Can J Ophthalmol* 1995;30(3):124–30.
- [23] Baumann A, Zimmerli S, Hausler R, Caversaccio M. Invasive sphenoidal aspergillosis: successful treatment with sphenoidotomy and voriconazole. *ORL J Otorhinolaryngol Relat Spec* 2007;69(2):121–6.
- [24] Chang T, Teng MM, Wang SF, Li WY, Cheng CC, Lirng JF. Aspergillosis of the paranasal sinuses. *Neuroradiology* 1992;34(6):520–3.
- [25] Munoz J, Kuriakose P. Antibiotic-refractory sinusitis. *J Am Med Assoc* 2012;308(22):2399–400.
- [26] Send T, Tuleta I, Koppen T, et al. Sarcoidosis of the paranasal sinuses. *Eur Arch Otorhinolaryngol* 2019;276(7):1969–74.
- [27] Yoshimoto R, Tanaka K, Kawahata T, et al. Unusual manifestations of giant cell arteritis and granulomatosis with polyangiitis. *Immunol Med* 2019;42(2):94–8.
- [28] Ramani R, Hazarika P, Kapadia RD, Shivananda PG. Invasive maxillary aspergillosis in an otherwise healthy individual. *Ear Nose Throat J* 1994;73(6):420–2.
- [29] Ota R, Katada A, Bando N, et al. A case of invasive paranasal aspergillosis that developed from a non-invasive form during 5-year follow-up. *Auris Nasus Larynx* 2010;37(2):250–4.